VOLITIONRX LTD
No SEC Form 4 filings for $VNRX in the last 30 days.
See all $VNRX insider activity →VolitionRx (VNRX) joins the €6.3M DETECSEPS Consortium in France to evaluate its Nu.Q® NETs assay for early sepsis detection. The project, funded by the French government, aims to improve patient outcomes and reduce healthcare burden. Volition provides the biomarker, while IDS France supplies the analyzer. Sepsis causes 21M deaths annually, with early detection crucial for treatment.
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Notes As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Glob
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 Reduces Equity Overhang Henderson, Nevada, September 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-n
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning VNRX (VOLITIONRX LTD). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent VNRX coverage spans corporate actions, financial news and technology.
The partnership could open a multi‑billion dollar market for sepsis testing, but the immediate financial impact is limited to the €6.3M grant.
Dilution from note conversion may modestly pressure share price.
Debt reduction may lift sentiment and support the stock short‑term.
Positive early data could boost investor sentiment and drive short‑term price appreciation as the market anticipates further validation and potential partnerships.
The waiver could enable the company to raise up to $10 million+ in equity, diluting shareholders but providing cash for operations.
AlphAI scores every news story that mentions VNRX with an AI model for sentiment and relevance, and aggregates insider trades from VOLITIONRX LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
VolitionRx (VNRX) joins the €6.3M DETECSEPS Consortium in France to evaluate its Nu.Q® NETs assay for early sepsis detection. The project, funded by the French government, aims to improve patient outcomes and reduce healthcare burden. Volition provides the biomarker, while IDS France supplies the analyzer. Sepsis causes 21M deaths annually, with early detection crucial for treatment.
2 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities Conversions of Notes As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Glob
1 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 Reduces Equity Overhang Henderson, Nevada, September 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-n
1 min readVolitionRx (VNRX) presented early-stage cancer detection data at ESMO MAP, showing 95% detection of stage I/II cancers using its Capture-Seq™ technology. The company targets a $36B market in early cancer detection and MRD, with plans to accelerate development and patent protection. Results showed no false positives in initial cohorts, with further studies underway.
2 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement . As previously reported, VolitionRx Limited (the “Company”) and Lind Global Asset Management XII LLC (“Lind”) entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026 (the “
1 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
1 min readVolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.
2 min readVolitionRx reported 112% H1 revenue growth to $1.4M. The company highlighted progress in sepsis testing, lung cancer reimbursement, and cancer detection. It also announced a collaboration with Sysmex Corporation and active licensing discussions with global diagnostic leaders. Volition aims for a $5M milestone in veterinary diagnostics and a reimbursement submission in France by year-end.
2 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
1 min readVOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit
3 min read
